Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.
about
Current Standard and Future Perspectives in Non-Surgical Therapy for Hepatocellular Carcinoma.T cell exhaustion: from pathophysiological basics to tumor immunotherapy.Advances and Future Directions in the Treatment of Hepatocellular CarcinomaPrecision medicine for hepatocellular carcinoma: driver mutations and targeted therapy.Chemotherapy for Hepatocellular Carcinoma: Current Evidence and Future PerspectivesCurrent immunotherapeutic strategies in hepatocellular carcinoma: recent advances and future directions.Immuno-thermal ablations - boosting the anticancer immune response.Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer.Impact of cavitron ultrasonic surgical aspirator (CUSA) and bipolar radiofrequency device (Habib-4X) based hepatectomy for hepatocellular carcinoma on tumour recurrence and disease-free survival.Targets for immunotherapy of liver cancer.Immunotherapy in managing metastatic melanoma: which treatment when?Nonalcoholic fatty liver disease promotes hepatocellular carcinoma through direct and indirect effects on hepatocytes.How does the tumor microenvironment play a role in hepatobiliary tumors?Enlighting the Shadow for Advanced Hepatocellular Carcinoma: Immunotherapy with Immune Checkpoint Inhibitors.miR-199a-3p Modulates MTOR and PAK4 Pathways and Inhibits Tumor Growth in a Hepatocellular Carcinoma Transgenic Mouse Model.Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations.Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma.Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinomaSystemic treatments for hepatocellular carcinoma: challenges and future perspectivesCurrent frontline approaches in the management of hepatocellular carcinoma: the evolving role of immunotherapyLong-term remission in advanced stage hepatocellular carcinoma? A chance for cure?Biomarkers for hepatocellular carcinoma: What's new on the horizon?Changing role of histopathology in the diagnosis and management of hepatocellular carcinomaMolecular Targets in Hepatocarcinogenesis and Implications for TherapyStudy to evaluate the immunomodulatory effects of radiofrequency ablation compared to surgical resection for liver cancerCheckpoint inhibitor use in two heart transplant patients with metastatic melanoma and review of high-risk populations
P2860
Q38671883-54EE5CB1-BCF6-4DB3-9E2D-87A1668A9B39Q39078341-549D411A-F281-4B8B-A609-5701526E49A4Q41531360-6D247B87-8E94-45FF-A624-106DBB06C18CQ41547474-2D1FD1A0-BE79-40F8-A1BD-E7F1561A5ACAQ41706847-FFE68DD5-AC41-4B06-8203-BA5A3B6855F3Q42375643-CBB80F5F-4457-403B-84DB-9E4959E03483Q42690545-A4F37BE5-6FF3-4EF5-9118-C462CDC72D98Q47119885-37E3A426-44F6-452C-9471-481BB9BC1FB8Q47154433-97BF03D5-535B-4CD4-9263-BE85C43D48FEQ47965755-00611382-73D8-4483-913A-5AED6C9DB188Q50166276-732929EF-7545-40D1-BDF5-ACFD4D512D4AQ50249485-6EADF179-C5AA-4622-9F3C-B03A5954B439Q52725074-90962871-7C0C-4FF4-9B8F-FBB5CAA71882Q53098420-75E1EC37-A26B-48E9-9BD0-19C9660ED979Q54963896-400EFABF-4E8D-447B-9928-0520E716DE4EQ54963955-0FEEC283-8CA6-4067-94D0-AE45BEB2C0C3Q55008075-B4400B42-5938-4132-816B-E7DA5A685359Q56890465-29CA2F65-F5EB-4EAA-B2B8-B8204B0A5995Q57301434-97502B80-1276-4B48-8067-750C52DEF5B3Q58117622-B2802405-B227-4DC5-8222-7EDCCEB8F4DDQ58704728-D635FBBC-97C6-4EB2-9F5E-1C8F488E6BE2Q58707823-E1C23A8C-3C19-4178-982E-0EE726433352Q58707841-1F6902DF-E7E6-4041-B76B-5F6029310DBFQ58784853-0DDACB67-F78C-4910-951F-A4905235FD01Q58798362-19BFCF55-9082-4312-95D8-D68E56F637C4Q59135661-05971672-6DD6-4E56-AA75-F017187B7B33
P2860
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Tremelimumab in combination wi ...... nced hepatocellular carcinoma.
@en
Tremelimumab in combination wi ...... nced hepatocellular carcinoma.
@nl
type
label
Tremelimumab in combination wi ...... nced hepatocellular carcinoma.
@en
Tremelimumab in combination wi ...... nced hepatocellular carcinoma.
@nl
prefLabel
Tremelimumab in combination wi ...... nced hepatocellular carcinoma.
@en
Tremelimumab in combination wi ...... nced hepatocellular carcinoma.
@nl
P2093
P2860
P1476
Tremelimumab in combination wi ...... nced hepatocellular carcinoma.
@en
P2093
Aradhana M Venkatesan
Ashish Uppala
Austin G Duffy
David E Kleiner
David Venzon
Drew Pratt
Elliot Levy
Firouzeh Korangy
Heiner Wedemeyer
Jeremy L Davis
P2860
P304
P356
10.1016/J.JHEP.2016.10.029
P577
2016-11-02T00:00:00Z